Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

→ Most important medical advance in 100 years (From The Oxford Club) (Ad)
Free ARTH Stock Alerts
$1.05
+0.01 (+0.96%)
(As of 05/17/2024 08:54 PM ET)
Compare
Today's Range
$1.02
▼
$1.14
50-Day Range
$0.93
▼
$2.14
52-Week Range
$0.39
▼
$18.00
Volume
3,900 shs
Average Volume
5,590 shs
Market Capitalization
$4.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
ARTH stock logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Stock Price History

ARTH Stock News Headlines

May 18 at 2:06 AM | americanbankingnews.com
Short Interest in Arch Therapeutics, Inc. (OTCMKTS:ARTH) Decreases By 5.3%
May 10, 2024 | americanbankingnews.com
Arch Therapeutics (OTCMKTS:ARTH) Stock Passes Below Fifty Day Moving Average of $1.60
May 6, 2024 | globenewswire.com
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
February 8, 2024 | msn.com
Arch Therapeutics Secures $750K Prepayment for Stock
January 6, 2024 | morningstar.com
Arch Therapeutics Inc ARTH
November 23, 2023 | msn.com
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
November 9, 2023 | finanznachrichten.de
Arch Therapeutics, Inc.: Arch Therapeutics Provides Year End Operational Update
November 9, 2023 | finance.yahoo.com
Arch Therapeutics Provides Year End Operational Update
November 2, 2023 | finance.yahoo.com
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
September 13, 2023 | finance.yahoo.com
Arch Therapeutics Provides AC5® Commercialization Update
September 8, 2023 | finanznachrichten.de
Arch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to Uplisting
September 7, 2023 | finance.yahoo.com
Arch Therapeutics Completes Financing as Bridge to Uplisting
July 8, 2023 | health.usnews.com
Dr. Arth Patel
June 13, 2023 | travel.usnews.com
Double Arch
April 25, 2023 | finance.yahoo.com
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
April 5, 2023 | finance.yahoo.com
Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
March 20, 2023 | investing.com
Arch Therapeutics Inc (ARTHD)
March 9, 2023 | finance.yahoo.com
Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
March 7, 2023 | finance.yahoo.com
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
February 23, 2023 | benzinga.com
Arch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and Revenue
January 24, 2023 | msn.com
Wound products developer Arch Therapeutics files for uplisting, $35M offering (update)
January 18, 2023 | finanznachrichten.de
Arch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
January 18, 2023 | finance.yahoo.com
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
January 17, 2023 | finance.yahoo.com
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
December 5, 2022 | finance.yahoo.com
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
See More Headlines

Company Calendar

Last Earnings
5/09/2024
Today
5/20/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
CUSIP
N/A
CIK
1537561
Web
www.archtherapeutics.com
Phone
(617) 431-2313
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,980,000.00
Net Margins
-6,460.51%
Pretax Margin
-6,460.51%
Return on Equity
N/A
Return on Assets
-489.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.02

Sales & Book Value

Annual Sales
$80,000.00
Price / Sales
62.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.43) per share
Price / Book
-0.43

Miscellaneous

Outstanding Shares
4,742,000
Free Float
4,529,000
Market Cap
$4.98 million
Optionable
Not Optionable
Beta
3.62

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 59)
    Co-Founder, Chairman, President & CEO
    Comp: $450.5k
  • Mr. Michael S. Abrams (Age 54)
    CFO & Treasurer
    Comp: $325k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Shawn Carlson
    Vice President of Sales

Key Competitors

View All Competitors

ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed in 2024?

Arch Therapeutics' stock was trading at $7.24 at the beginning of the year. Since then, ARTH stock has decreased by 85.5% and is now trading at $1.05.
View the best growth stocks for 2024 here.

Are investors shorting Arch Therapeutics?

Arch Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totaling 12,400 shares, a decrease of 5.3% from the April 15th total of 13,100 shares. Based on an average daily volume of 4,300 shares, the days-to-cover ratio is currently 2.9 days.
View Arch Therapeutics' Short Interest.

When is Arch Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ARTH earnings forecast.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.33) EPS for the quarter. The biotechnology company had revenue of $0.03 million for the quarter.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ARTH) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
"The Biggest Drug Ever" Is Coming
Behind the Markets
Most important medical advance in 100 years
The Oxford Club
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star